Supernus Pharmaceuticals, Inc. (SUPN) Dividend History

Company News

• Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

  Supernus Pharmaceuticals announced the expiration of the HSR Act waiting period for its proposed acquisition of Sage Therapeutics, with the tender offer continuing and set to expire on July 30, 2025.

  Benzinga

  Featured Companies: SAGE
• Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

  Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will host a conference call on February 25, 2025, to discuss its fourth quarter and full-year 2024 financial results.

  GlobeNewswire Inc.
• Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?

  Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.

  Zacks Investment Research
• Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

  Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.

  The Motley Fool
• This simple strategy of picking cheap stocks has been a repeat winner. Here are a few dozen names to get you started.

  MKM Partners' JC O'Hara says a simple strategy of picking the cheapest stocks at the start of the year, and then rebalancing, has been a winner through the years.

  MarketWatch

  Featured Companies: AAPL ABBV ABC ADM AHH AMAT APLE ARE ARW ASIX AVGO AVNT BCC BKH CI CVX DIOD DVN EIX ETR F FCX FFIV FTK FULT GLPI GPC HAL HUN HWC KNX KR LITE LOW MO MOS MU MUR NI NOC NSC NTAP OGS PFS PLYM PRU PWR QCOM SRE STZ TOL TSLA UPS WBA WNC WTFC XOM ZION